ScreenerHero

CNSP CNS Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · cnspharma.com
5.430USD+2.42%Mkt Cap: 7.94M $P/E: —

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.94M USD
Enterprise Value-12.24M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.85M USD
Revenue/Share—
Last Price5.430 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.59
PEG—
EV/EBITDA0.72
EV/Revenue—
P/S—
P/B0.43
EPS (TTM)-17.70
EPS (Forward)-0.39
52W Range
1.90041% of range10.59
52W High10.59 USD
52W Low1.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-350.48%
ROA-183.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.81M USD
CapEx (TTM)18.18K USD
FCF Margin—
FCF Yield-100.04%
Net Debt-19.98M USD
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity0.07
Current Ratio5.87
Quick Ratio5.35
Book Value/Sh12.45 USD
Cash/Share13.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 22, 2025
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Upside (mean)+84.2%
Target Range10.00 USD – 10.00 USD
# Analysts1
Ownership
Shares Out.1.46M
Float1.32M
Insiders0.95%
Institutions21.25%
Short Interest
Short Ratio0.3d
Short % Float0.20%
Short % Out.0.20%
Shares Short2.97K
Short (prev mo.)12.60K
Technical
SMA 505.465 (-0.6%)
SMA 2004.675 (+16.1%)
Beta1.02
S&P 52W Chg16.45%
Avg Vol (30d)5.90K
Avg Vol (10d)3.34K
Technical Indicators
RSI (14)52.0
MACD-0.0526
MACD Signal-0.0632
MACD Hist.+0.0106
BB Upper5.985 USD
BB Middle5.371 USD
BB Lower4.757 USD
BB Width22.87%
ATR (14)0.2715 USD
Vol Ratio (20d)0.60x